Aim: To assess whether in early (rheumatoid) arthritis (RA) patients, metacarpal bone mineral density (BMD) loss after 4 months predicts radiological progression after 1 year of anti-rheumatic treatment.
INTRODUCTION
Early treatment of patients with rheumatoid arthritis (RA) improves disease outcomes including radiological joint damage. [1] [2] [3] Identification of patients who will have a more severe disease course may steer early treatment strategies. Since predicting disease outcome is currently not possible in a reliable way for all patients, there is a need for new predictors to improve existing prediction models. [4] [5] [6] [7] Peri-articular osteopenia is one of the earliest radiological manifestations in RA and may already be found in the phase of undifferentiated arthritis (UA). 8, 9 Metacarpal bone mineral density (BMD) loss may therefore be a potentially new predictor of disease outcome in patients with early (rheumatoid) arthritis. Previous research showed that metacarpal BMD loss is associated with disease activity 10 and metacarpal BMD loss in the first year after diagnosis is predictive for radiological damage up to five years in patients with early RA. [11] [12] [13] For clinical practice however, any predictive value of metacarpal BMD loss would be greater if it can be measured earlier in the disease course.
Therefore we investigated whether metacarpal BMD loss after four months of treatment, as measured by Digital X-ray Radiogrammetry (DXR-BMD), may be a predictor of radiological joint damage progression after one year in patients with undifferentiated or early rheumatoid arthritis treated according to a tight control, remission steered treatment strategy.
PATIENTS AND METHODS

Patients and study design
Data from the IMPROVED study were used, a multicenter, randomized clinical trial in 610 patients, including 479 (80%) patients with recent onset RA (according to the 2010 classification criteria for RA 14 with a symptom duration <2 years), 122 patients with UA (having at least 1 joint clinically assessed as 'arthritis' and 1 other painful joint, clinically suspected of having early RA, regardless of symptom duration) and 9 patients that could not be classified because of missing data. Patients were treated according to a tight control strategy, aimed at achieving remission, defined as a DAS<1.6 (DAS-remission). 15 All patients started with 4 months of methotrexate (MTX) 25 mg/week and prednisone 60 mg/day tapered to a stable dose of 7.5 mg/day in 7 weeks. Patients in DAS-remission after 4 months started tapering medication, if possible to drug free (early DAS remission group). Patients not in early DASremission were randomized either to MTX 25 mg/wk plus hydroxychloroquine (HCQ) 400mg/ day, sulphasalazine (SSZ) 2000mg/day and prednisone 7.5mg/day (arm 1) or to MTX 25mg/wk plus adalimumab (ADA) 40mg/2weeks (arm 2). Some patient who were not in DAS-remission after 4 months, were not randomized and treated outside of protocol (Outside of Protocol (OP) group). Full details about the IMPROVED study protocol were previously published. 16, 17 In the current analysis we included all patients participating in the IMPROVED study of whom radiologic progression data after 1 year and at least 1 DXR-BMD result during the first year were available. 115 
Demographic and clinical variables
At baseline the following variables were collected: age, gender, symptom duration, body mass index, current smoking status and alcohol use, calcium intake, postmenopausal status, previous fractures, family history on osteoporosis, anti-citrullinated protein antibody (ACPA) and Rheumatoid Factor (RF) status. At baseline and every 4 months, the following clinical and laboratory variables were collected: Disease Activity Score (DAS), including Ritchie Articular Index (RAI), swollen joint count, erythrocyte sedimentation rate (ESR, mm/hr) and visual analogue scale (VAS) for global health, and C-reactive protein (CRP). During the first year, X-rays of hand and feet were made 4 monthly by digital radiography in all patients. Radiological progression, scored using the Sharp/van der Heijde scoring method, was assessed by two independent readers blinded for patient identity and time order of the radiographs. 18 Progression was defined as an increase in Sharp-van der Heijde Score (SHS) of ≥0.5 points. Details on inter-reader reliability were previously published.
17
Metacarpal BMD measurements Suitable routine digital X-rays of both hands were used to measure metacarpal BMD using Digital X-ray Radiogrammetry (DXR-BMD) measured by DXR-online (Sectra, Linköping, Sweden), a computerised method which automatically recognises three regions of interest on the second, third and fourth metacarpal bone. At each region, DXR-BMD is estimated from multiple measurements of cortical thickness, bone width and porosity. 19 The mean value of both hands was used in all analyses to avoid bias induced by hand dominance. 'DXR-BMD loss' was defined as a loss in DXR-BMD of ≥1.5 mg/cm 2 /4months. 10 
Statistical analysis
Almost half of the available X-rays were found unsuitable for DXR-measurements. This resulted in missing DXR-BMD values in 141/428 patients (33%) at baseline, 73/428 (17%) after 4 months, 148/428 (35%) after 8 months and 140/428 (33%) after 1 year. To avoid possible bias induced by missing data and to increase power, multiple imputation was performed. Ten datasets were created in which missing DXR-values were imputed based on a linear regression model fitting available patient and disease characteristics and DXR-values. 20 Estimates obtained from regression analyses were automatically pooled by SPSS, other multiple estimates were averaged.
Median (IQR) DXR-BMD changes were shown because of a skewed distribution. Mann Whitney U test was used for comparisons of DXR-BMD changes between patients with and without radiological progression. To identify independent predictors of radiological progression we performed univariate followed by multivariate regression analyses. From previous literature, the following potential predictors for (rapid) radiological progression were identified and entered in a univariate logistic regression model with radiologic progression (yes/no) as dependent variable: presence of ACPA and/or RF, baseline swollen joint count, baseline ESR and CRP levels, baseline total SHS, baseline erosion score and treatment. 4, 6, 7 In addition, we selected age, gender, fulfilling the 2010 ACR/EULAR criteria for RA and achieving DAS-remission after 4 months. Next to baseline erosion score we also entered presence of erosions, defined as ≥1 erosions, as covariate. Because only 28 (7%) patients included in this analysis had radiological progression, multivariate regression in the total study population was powered for about three variables. 21, 22 Therefore, in addition to DXR-BMD loss from baseline to 4 months, those 2 univariate significant predictors (using a significance level of 0.10) with the highest effect size were selected for multiple regression. As radiologic progression was present in <10% of the patients and therefore can be classified as 'rare' , we argued that Odds Ratios (OR) obtained from all logistic regression analyses can be interpreted as relative risks (RR). 23 All statistical analyses were conducted with SPSS for Windows version 20.0 (SPSS Inc., Chicago, IL).
RESULTS
Clinical characteristics
We included 428 patients in the current analysis. Baseline characteristics of these patients did not differ significantly from those participating in the IMPROVED study where no SHS or DXR data were available (data not shown). Twenty eight (7%) patients had radiological progression after 1 year and 400 (93%) had not. Of those with radiological progression, median (IQR) progression score was 0.5 (0.5-1.4). One patient had rapid radiological progression (progression score ≥5 points) 24 after 1 year (18 points).
Compared to patients without progression, patients with progression were older, more often postmenopausal, ACPA positive, and more often fulfilled the 2010 criteria for RA. Furthermore, they had more often ≥1 erosions at baseline and a higher median total baseline SHS and, only at 8 months, a slightly higher DAS (table 1) . Table 2 shows absolute DXR-BMD values and DXR-BMD changes during the first year. Compared to patients without radiological progression after 1 year, patients with radiological progression had lower absolute DXR-BMD values at baseline and after 4, 8 and 12 months follow up. From baseline to 4 months, median DXR-BMD changes were significantly larger in patients with radiological progression (median (IQR) -9.6 (-15.2;-2.7) than in patients without (-2.0 (-7.2;2.5), p=0.007). Twenty four (86%) patients with radiological progression had DXR-BMD loss within the first 4 months, compared to 212 (53%) patients without radiological progression (p=0.01). The one patient with rapid radiological progression (18 points after 1 year) had DXR-BMD loss within the first 4 months of 27.4 mg/cm 2 .
DXR-BMD change
Treatment steps
Seventeen (61%) patients with radiological progression after 1 year had been in early DAS-remission after 4 months and subsequently had started tapering prednisone to 
Presence of erosions, n (%) 62 (14) 11 ( zero, 9 (32%) had not achieved early remission and were randomized, and 2 were treated outside the protocol. Of those 17 in early DAS-remission, 5 patients relapsed after tapering prednisone and restarted it, whereas 12 remained in remission and started tapering MTX to zero. Six patients relapsed after tapering MTX and restarted it and 6 did not relapse and were in drug free remission after 1 year. The median (IQR) early DXR-BMD change of all 17 patients was -10.9 (-14.5;-2.5) mg/cm 2 (corresponding to -2.7 (-3.6;-0.6 mg/cm 2 /month)), compared to -1.8 (-7.3;2.4) mg/cm 2 (corresponding to -0.5 (-1.8;0.6 mg/cm 2 /month) in 258 patients who achieved early DAS-remission and had no radiological progression after 1 year (p=0.02). DXR-BMD loss after 4 months was present in 14/17 (82%) patients in early DAS-remission who had radiological progression after 1 year, compared to 134 (52%) patients in early DAS-remission without radiological progression after 1 year (p=0.053).
Predictors of radiological progression
Univariate predictive variables for radiologic progression after 1 year were: fulfilling the 2010 criteria for RA (p=0.07), presence of baseline erosions (yes/no) (p<0.001), presence of both ACPA and RF (p=0.03), early DXR-BMD loss after 4 months (p=0.008), baseline total SHS score (p=0.07), age (p=0.01), baseline ESR (p=0.06) and TJC (p=0.05). Female gender, presence of either ACPA or RF, symptom duration, baseline erosion score and CRP level and treatment group were not predictive. Achieving DAS-remission after 4 months was also not predictive for radiological progression after 1 year (table 3a) .
Together with early DXR-BMD loss, presence of baseline erosions and fulfilling the 2010 criteria for RA were selected for inclusion in the multivariate regression analysis. Both Table 2 . DXR-BMD measurements and changes in DXR-BMD during the first study year of the total study population and separate for patients with and without radiological progression.
Time point (months)
Total n=428 metacarpal bone mineral density measured by digital X-ray radiogrammetry, erosion score: Sharp-van der Heijde erosion score, tSHS: total Sharp-van der Heijde Score, ESR: erythrocyte sedimentation rate in mm/hr, CRP: C-reactive protein, TJC: tender joint count, early remission group: patients who were in remission after 4 months and started tapering medication, arm 1: patients not in early remission who were randomized to methotrexate (MTX), sulfasalazine (SSZ), hydroxychloroquine (HCQ) and low dose prednisone, arm 2: patients not in early remission who were randomized to MTX plus adalimumab, early DAS-remission: remission (DAS<1.6) after 4 months.
SHS progression p-value
presence of baseline erosions and early DXR-BMD loss were predictive for radiological progression after one year independent of each other and independent of fulfilling the 2010 criteria for RA (table 3b) .
In an additional multivariate model including DXR-BMD loss, presence of baseline erosions and presence of both ACPA and RF, presence of both ACPA and RF was not an independent predictor for radiological progression, whereas DXR-BMD loss and presence of baseline erosions both were (data not shown).
After leaving out the one patient with rapid radiological progression (18 points after 1 year), the results above did not significantly change (data not shown).
Patients without baseline erosions
In 366 (86%) patients no baseline erosions were present, of which 17 patients (5%) showed radiological progression after 1 year (61% of all 28 patients with radiological progression) and 349 (95%) did not. Median DXR-BMD change from baseline to 4 months was -11.8 (-16.7;-4.7) in patients with progression and -2.0 (-7.0;2.4) mg/cm 2 in patients without (corresponding to -2.9 (-4.2;-1.2) and -0.5 (-1.7;0.6) mg/cm 2 /months, respectively). Univariate significant predictors for progression after 1 year in patients without baseline erosions were age (p=0.004), baseline total SHS (in these patients reflecting baseline joint space narrowing) (p=0.009), baseline ESR level (p=0.096) and early DXR-BMD loss (p=0.02) (table 4a).
Early DXR-BMD loss and total baseline SHS were selected for entering in the multivariate regression analysis. Early DXR-BMD loss was predictive for radiological progression after 1 year independent of baseline total SHS in patients without baseline erosions (table 4b) .
DISCUSSION
In patients with early rheumatoid or undifferentiated arthritis, metacarpal BMD loss measured by DXR after four months of treatment with MTX and a tapered high dose of prednisone is predictive for future joint damage after 1 year of remission steered treatment. In patients without baseline erosions (86%) metacarpal BMD loss was the main predictor for future joint damage.
These data suggest that DXR measurements over a period of 4 months from baseline can help to decide which patients with early arthritis should start anti-rheumatic treatment to prevent joint damage or damage progression, one of the main goals in treatment of RA. 25 Early treatment and suppression of disease activity has been shown to be associated with better suppression of radiological damage progression. [1] [2] [3] To facilitate this, in 2010 new classification criteria for RA have been formulated. 14 In the IMPROVED trial we included patients with RA (according to the 2010 classification criteria) but also patients with UA, who were judged to represent RA in an early phase of the disease by the treating rheumatologist. Starting treatment this early in disease course carries the risk of overtreatment of patients who are misdiagnosed as RA, but a treatment delay means risking irreversible joint damage progression. RA: rheumatoid arthritis (according to 2010 ACR/EULAR classification criteria), ACPA: anti-citrullinated protein antibody, RF: rheumatoid factor, DXR-BMD: metacarpal bone mineral density measured by digital X-ray radiogrammetry, SHS: Sharp-van der Heijde Score, ESR: erythrocyte sedimentation rate in mm/hr, CRP: C-reactive protein, TJC: tender joint count, early remission group: patients who were in remission after 4 months and started tapering medication, arm 1: patients not in early remission who were randomized to methotrexate (MTX), sulfasalazine (SSZ), hydroxychloroquine (HCQ) and low dose prednisone, arm 2: patients not in early remission who were randomized to MTX plus adalimumab, early DAS-remission: remission (DAS<1.6) after 4 months. To individualize treatment, predictive factors for damage progression have been identified and prediction models build. 4, 6, 7 But in particular in patients without baseline damage, predicting who will develop joint damage may be difficult. We looked at metacarpal BMD loss since this was linked with both disease activity and joint damage 122 progression in patients with early and established RA, and metacarpal BMD loss after 1 year has been shown to have predictive value additional to known predictors. 11, 12 Our paper is the first to report metacarpal BMD changes already after 4 months, and we found that changes indeed occur.
Ideally, an outcome predictor can be identified already at baseline. In this early arthritis population, presence of baseline erosions was the only independent baseline predictor for radiological progression after 1 year besides metacarpal BMD loss after 4 months. Another obvious outcome after 4 months, remission yes or no, was not predictive of progression after 1 year. Some patients who had radiological joint damage after 1 year even were in remission throughout the whole year and tapered all medication according to the study protocol. Our results indicate that after 4 months, a strong predictor of progression may help to decide if adjustments of the chosen treatment strategy should be made in patients with early arthritis.
One limitation of this study may be the fact that, due to the inclusion of patients with early and relatively mild disease, progressively treated with the aim of achieving remission, only very few patients had radiological damage progression. Our results however reached statistical significance, although we acknowledge that the damage scores are hardly of clinical relevance this early in the disease phase. But as RA treatment more and more aims at achieving total disease and damage control in an early phase of the disease, we think that our findings may be relevant for daily practice.
Another limitation was that we found many of the 'routinely' acquired radiographs unsuitable for DXR. To handle missing metacarpal BMD data we performed multiple imputation 20 to account for potential bias caused by data 'missing at random' , meaning that missingness depends on other observed patient characteristics than on the fact that metacarpal BMD measurements were possible or not.
A third possible limitation may be that, as DXR-measurements in this study were done in retrospect on X-rays made in 12 different hospitals using imaging protocols not adjusted to DXR, precision of the method may be lower than previously published. DXR-BMD has been shown to have a very high short and long term precision in both in vitro cadaver studies (coefficients of variation (CV) of 0.22 to 1%) and in one cohort study and one clinical trial (CV of 0.25 to 0.46%). [26] [27] [28] [29] However, supported by the consistency of our results, precision in this study may still be considered as high.
If metacarpal BMD will be applied in clinical practice using the DXR online method, neither low precision or missing values may be problematic, as X-rays will then be made according to a predefined protocol (Sectra, Sweden). Precision may reach values described above, and in case of mal positioning, direct feedback will be given, which makes it more suitable for use in clinical practice.
In conclusion, we showed that loss of metacarpal bone mineral density measured by DXR after the first 4 months of treatment is an independent predictor of future bone damage in patients with early (rheumatoid) arthritis. This suggests that 4 monthly metacarpal BMD measurements could help to guide treatment decisions in individual patients or may be added to improve the predictive value of existing prediction models for disease outcome in RA.
